JMP Securities Increases Mirum Pharmaceuticals (NASDAQ:MIRM) Price Target to $72.00

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by stock analysts at JMP Securities from $69.00 to $72.00 in a report issued on Thursday, Benzinga reports. The brokerage currently has an “outperform” rating on the stock. JMP Securities’ target price suggests a potential upside of 177.14% from the company’s current price.

MIRM has been the subject of several other reports. Raymond James decreased their price target on shares of Mirum Pharmaceuticals from $78.00 to $64.00 and set a “strong-buy” rating for the company in a research note on Tuesday, December 19th. JPMorgan Chase & Co. reissued an “overweight” rating and issued a $37.00 target price on shares of Mirum Pharmaceuticals in a research note on Monday, November 20th. HC Wainwright decreased their target price on shares of Mirum Pharmaceuticals from $58.00 to $45.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Cantor Fitzgerald reissued an “overweight” rating and issued a $35.00 target price on shares of Mirum Pharmaceuticals in a research note on Thursday, February 29th. Finally, SVB Leerink decreased their target price on shares of Mirum Pharmaceuticals from $44.00 to $43.00 and set an “outperform” rating for the company in a research note on Monday. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $52.11.

Mirum Pharmaceuticals Stock Down 3.0 %

Shares of MIRM traded down $0.79 during mid-day trading on Thursday, hitting $25.98. 789,916 shares of the company’s stock were exchanged, compared to its average volume of 610,994. The company has a market cap of $1.21 billion, a PE ratio of -6.54 and a beta of 1.16. Mirum Pharmaceuticals has a 52 week low of $21.83 and a 52 week high of $35.56. The company has a 50-day simple moving average of $27.59 and a 200 day simple moving average of $29.30. The company has a debt-to-equity ratio of 1.14, a current ratio of 5.20 and a quick ratio of 4.91.

Insiders Place Their Bets

In other Mirum Pharmaceuticals news, insider Lara Longpre sold 1,019 shares of Mirum Pharmaceuticals stock in a transaction on Monday, January 8th. The shares were sold at an average price of $28.04, for a total transaction of $28,572.76. Following the completion of the transaction, the insider now directly owns 105,254 shares of the company’s stock, valued at $2,951,322.16. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, CEO Christopher Peetz sold 5,209 shares of Mirum Pharmaceuticals stock in a transaction on Monday, January 8th. The stock was sold at an average price of $28.03, for a total transaction of $146,008.27. Following the completion of the sale, the chief executive officer now owns 110,125 shares of the company’s stock, valued at $3,086,803.75. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Lara Longpre sold 1,019 shares of Mirum Pharmaceuticals stock in a transaction on Monday, January 8th. The stock was sold at an average price of $28.04, for a total value of $28,572.76. Following the sale, the insider now directly owns 105,254 shares of the company’s stock, valued at approximately $2,951,322.16. The disclosure for this sale can be found here. Insiders sold a total of 8,899 shares of company stock valued at $248,102 over the last ninety days. 24.06% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Mirum Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Mirum Pharmaceuticals by 98.0% during the third quarter. China Universal Asset Management Co. Ltd. now owns 986 shares of the company’s stock worth $31,000 after buying an additional 488 shares in the last quarter. Metropolitan Life Insurance Co NY raised its stake in Mirum Pharmaceuticals by 49.7% in the second quarter. Metropolitan Life Insurance Co NY now owns 1,464 shares of the company’s stock valued at $38,000 after purchasing an additional 486 shares in the last quarter. AJOVista LLC acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $40,000. Wetzel Investment Advisors Inc. acquired a new position in Mirum Pharmaceuticals in the fourth quarter valued at about $41,000. Finally, Tower Research Capital LLC TRC raised its stake in Mirum Pharmaceuticals by 186.6% in the second quarter. Tower Research Capital LLC TRC now owns 1,846 shares of the company’s stock valued at $48,000 after purchasing an additional 1,202 shares in the last quarter.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease.